FDA recalls two injectable medicines in late April and May 2026

The FDA posted two hospital-level recalls of injectable medicines in late April and mid-May 2026. One involves doxorubicin hydrochloride liposome injection; the other involves Lactated Ringer’s Injection. In both cases, the concern is particulate contamination in products meant to be given by injection or infusion.

For most readers, the main takeaway is practical: this is primarily a safety and supply issue for hospitals, clinics, pharmacists, and infusion teams. It is not a reason to panic, but it is reasonable to ask whether any medication you are scheduled to receive is part of a recall.

What FDA posted and when

FDA posted Sun Pharmaceutical Industries’ doxorubicin recall notice on May 13, 2026. The company recalled one lot of doxorubicin hydrochloride liposome injection 50 mg/25 mL because of possible glass particles in some vials.

FDA posted B. Braun’s Lactated Ringer’s recall notice on April 28, 2026. That recall covers two lots of Lactated Ringer’s Injection, 1L, because of particulate matter in solution.

FDA’s drug recall resources explain how the agency posts recall information and current recall listings. FDA also notes that recalls can create temporary access or substitution issues when health systems must switch products.

Why particles in injectable medicines matter

Particles in an injectable product can be more than a quality concern. If particles enter the bloodstream, they can irritate tissue or blood vessels and may contribute to blockage, inflammation, or other serious harm depending on the product and the amount involved.

The CDC says medication safety practices are important because safe preparation and administration help prevent avoidable harm. For recalled injectables, hospitals and pharmacies generally need to identify affected lots, stop use, quarantine stock, and arrange return or replacement.

What the doxorubicin recall says

According to Sun Pharma and FDA, the recall covers doxorubicin hydrochloride liposome injection 50 mg/25 mL sold under the Aisling label. The company said the lot was recalled to the hospital/user level because glass particles were detected during production. At the time of the notice, no adverse events had been reported for the lot.

The product is used for certain cancers, including ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. The recall notice says hospitals, distributors, and other users with the product should stop using it and follow the instructions in the recall communication.

What the Lactated Ringer’s recall says

FDA’s April 28 notice says B. Braun recalled two lots of Lactated Ringer’s Injection, 1L, to the hospital and healthcare-facility level because of particulate matter in solution. The company said the particles were identified through complaint investigations and that no adverse events had been reported at the time of the notice.

B. Braun warned that if particulate matter is infused, it could cause patient harm and may require additional medical intervention. The notice also says the product could carry a reasonable probability of causing pulmonary emboli, vessel occlusions, or phlebitis.

Who may have been exposed and how hospitals should check

The people most likely to be affected are patients who received one of the recalled lots and the clinicians, pharmacists, and supply teams responsible for inventory and dispensing. Because both recalls are at the hospital or healthcare-facility level, many patients may never see the product directly.

Health systems should check lot numbers against the recall notices, quarantine affected stock, and confirm whether any recalled vials or bags were used before the recall was identified. If a patient may have received a recalled product, the care team should review the chart, monitor for possible complications, and follow recall reporting procedures.

What patients can ask their care team

If you are receiving infusion therapy, chemotherapy, IV fluids, or another injectable treatment, you can ask:

Was any medication or IV fluid I received part of an FDA recall?
If a recalled lot was used, what symptoms should I watch for?
Do you need to document this in my chart or report it?
Will my treatment schedule change because of the recall or a temporary substitution?

If you develop new or severe symptoms after an infusion, contact your care team promptly. Seek urgent care or emergency help right away for trouble breathing, chest pain, fainting, severe swelling, or sudden worsening pain.

What remains uncertain

The recall notices explain the quality problem and the recall scope, but they do not prove that every exposed patient was harmed. The clinical impact depends on whether the product was actually administered, how much was used, and whether particles were present in the specific dose a patient received.

It is also not yet clear whether either recall will cause broader access problems beyond the affected lots. FDA’s drug shortage resources may be useful if hospitals need substitutes or alternate suppliers.

What readers can do now

Most patients do not need to take action unless they were told they may have received a recalled lot or they are scheduled for an infusion soon. If you are unsure, ask your pharmacist, infusion center, or clinician whether the product used for your care is affected. Do not stop or change any prescribed treatment on your own.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.